SELECTBIO - Antibodies in Drug Discovery Biographies

Home

Agenda

Keynote Speakers

Registration

Exhibition

Venue

Workshops

Co-Located Conferences

Social Program

Monoclonal Antibody Therapy for the Management of Severe Asthma

Monday, 6 March 2017 at 10:00

Add to Calendar ▼2017-03-06 10:00:002017-03-06 11:00:00Europe/LondonMonoclonal Antibody Therapy for the Management of Severe AsthmaSELECTBIOenquiries@selectbiosciences.com

Severe asthma involves a number of variants with different underlying pathologies. Genome Wide Association Studies have consistently implicated IL-33 and its receptor ST2 in asthma. IL-33 itself has intriguing biochemistry that has implications for antibody discovery.

Suzanne Cohen, , MedImmune

Suzanne joined MedImmune in 2001 after gaining a doctorate in Immunology at the University of Oxford, UK. She has over 15 years experience in preclinical and early clinical development of therapeutic antibodies and currently leads a team focused on lung disease research in the department of Respiratory, Inflammation and Autoimmunity (RIA) in Cambridge, UK.